Evogene Ltd. (EVGN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1125448,
    "name": "Evogene Ltd.",
    "stock_name": "Evogene Ltd.",
    "full_name": "Evogene Ltd.",
    "name_url": "stocks-analysis/evogene",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "1.10",
    "chg": 0.05,
    "chgp": "4.27%",
    "dir": 1,
    "prev_price": "1.05",
    "mcapval": "11.07",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "IL0011050551",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "35.18 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/evogene-1125448-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Evogene Ltd. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-evogene-ltd-technically-bullish-or-bearish-3548940",
        "imagepath": "",
        "date": "2025-09-20 20:28:55",
        "description": "As of 21 February 2025, the technical trend for Evogene Ltd. has changed from bearish to mildly bearish. The current price is 1.22, showing slight movement from the previous close of 1.21. Despite this minor uptick, the stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -34.60% compared to the S&P 500's 12.22%, and a one-year return of -55.36% versus 17.14%. This indicates a weak technical stance overall...."
      },
      {
        "title": "Is Evogene Ltd. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-evogene-ltd-overvalued-or-undervalued-3544520",
        "imagepath": "",
        "date": "2025-09-20 18:48:27",
        "description": "As of 31 August 2022, the valuation grade for Evogene Ltd. moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company appears to be overvalued given its negative price-to-book value of -2.01, an EV to EBIT ratio of 0.08, and an EV to EBITDA ratio of 0.09, which suggest that the market is pricing the stock unfavorably compared to its earnings potential. \n\nIn comparison to peers, Evogene Ltd. has a valuation ratio of -0.7507, which is notably lower than the industry average. This further reinforces the notion that the company is not positioned favorably within its sector. Additionally, the stock has underperformed significantly against the S&P 500, with a year-to-date return of -34.60% compared to the index's 12.22%, highlighting the challenges facing the company in the current market environment...."
      }
    ],
    "total": 7,
    "sid": "1125448",
    "stock_news_url": "https://www.marketsmojo.com/news/evogene-1125448"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Evogene Ltd. technically bullish or bearish?

2025-09-20 20:28:55

As of 21 February 2025, the technical trend for Evogene Ltd. has changed from bearish to mildly bearish. The current price is 1.22, showing slight movement from the previous close of 1.21. Despite this minor uptick, the stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -34.60% compared to the S&P 500's 12.22%, and a one-year return of -55.36% versus 17.14%. This indicates a weak technical stance overall....

Is Evogene Ltd. overvalued or undervalued?

2025-09-20 18:48:27

As of 31 August 2022, the valuation grade for Evogene Ltd. moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company appears to be overvalued given its negative price-to-book value of -2.01, an EV to EBIT ratio of 0.08, and an EV to EBITDA ratio of 0.09, which suggest that the market is pricing the stock unfavorably compared to its earnings potential. In comparison to peers, Evogene Ltd. has a valuation ratio of -0.7507, which is notably lower than the industry average. This further reinforces the notion that the company is not positioned favorably within its sector. Additionally, the stock has underperformed significantly against the S&P 500, with a year-to-date return of -34.60% compared to the index's 12.22%, highlighting the challenges facing the company in the current market environment....

View All News